AC Immune SA (NASDAQ:ACIU) has received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price target of $23.50 for the company and are predicting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned AC Immune an industry rank of 179 out of 265 based on the ratings given to related companies.
A number of research firms have recently weighed in on ACIU. BidaskClub downgraded shares of AC Immune from a “strong-buy” rating to a “buy” rating in a research report on Friday. Zacks Investment Research downgraded shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th.
Shares of AC Immune (ACIU) opened at $13.14 on Friday. AC Immune has a 1 year low of $6.03 and a 1 year high of $13.75.
AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. sell-side analysts expect that AC Immune will post -0.57 earnings per share for the current fiscal year.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.